Clinical trials: Cancer of Kidney
Select Advanced Malignancies, Kidney Cancer
A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies
To evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination with Durvalumab versus Nivolumab Monotherapy in Participants with Select Advanced Malignancies.
- Conditions
- Select Advanced Malignancies, Kidney Cancer, Clear Cell Renal Cell Carcinoma
- Trial name
- NCT02118337
- Testing
- MEDI0680, Durvalumab, Nivolumab
- Where
- 27 sites in United States, Australia and 4 more
- Volunteers
- 97 people
- Sponsor
- MedImmune LLC
Renal Cell Cancer, Stage IV Renal Cell Cancer
Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery
RATIONALE: Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Recombinant interferon alfa-2b may interfere with the growth of cancer cells and slow the growth of kidney cancer.
- Trial name
- NCT01158534
- Testing
- celecoxib, recombinant interferon alfa-2b, polymerase chain reaction
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Case Comprehensive Cancer Center
Multiple Myeloma, Advanced Solid Tumors
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Participants With Normal Renal Function or Severe Renal Impairment
The purpose of this study is to characterize the single-dose pharmacokinetic (PK) parameters of ixazomib (MLN9708) in cancer participants with either normal renal function or severe renal impairment (RI), including participants…
- Trial name
- NCT01830816
- Testing
- Ixazomib
- Where
- 11 sites in United States, Canada
- Volunteers
- 41 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Kidney Cancer, Renal Cell Carcinoma
Zoledronate With Atorvastatin in Renal Cell Carcinoma
Objectives: Primary: Evaluate clinical outcome based on the time to skeletal events after bone-targeted therapy Secondary: 1. Evaluate clinical outcome based on the presence of calcification at the site of osteolytic metastases…
- Trial name
- NCT00490698
- Testing
- Zoledronate, Atorvastatin
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- M.D. Anderson Cancer Center
Renal Cell Carcinoma (RCC), Urothelial Carcinoma
A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors
This is a Phase 1b/2, open-label, multicenter study of DSP-7888 Dosing Emulsion in combination with checkpoint inhibitors (nivolumab or pembrolizumab) in adult patients with solid tumors, that consists of 2 parts: dose search…
- Conditions
- Renal Cell Carcinoma (RCC), Urothelial Carcinoma, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer (PROC)
- Trial name
- NCT03311334
- Testing
- DSP-7888 Dosing Emulsion, Nivolumab, Pembrolizumab
- Where
- 19 sites in United States, Canada
- Volunteers
- 47 people
- Sponsor
- Sumitomo Pharma America, Inc.
Renal Cell Carcinoma
Phase I Biomarker Study (BMS-936558)
The purpose of this study is to evaluate the pharmacodynamic and biologic properties of BMS-936558 in subjects with metastatic renal cell carcinoma.
- Trial name
- NCT01358721
- Testing
- BMS-936558 (Anti-PD-1)
- Where
- 14 sites in United States, France and 1 more
- Volunteers
- 119 people
- Sponsor
- Bristol-Myers Squibb
Skin Neoplasms, Kidney Transplantation
Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients
The purpose of this study is to determine the effect of sirolimus on the prevention of new non-melanoma skin cancer (NMSC) in kidney transplant recipients.
- Trial name
- NCT00129961
- Testing
- sirolimus, cyclosporine or tacrolimus
- Where
- 23 sites in United States, Australia and 2 more
- Volunteers
- 86 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Kidney Cancer
Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma
The goal of this clinical research study is to compare the effectiveness of Afinitor (everolimus) and Sutent (sunitinib) for the treatment of advanced renal cell carcinoma (kidney cancer).
- Trial name
- NCT01185366
- Testing
- Everolimus, Sunitinib
- Where
- 4 sites in United States
- Volunteers
- 73 people
- Sponsor
- M.D. Anderson Cancer Center
Renal Cell Cancer, Renal Cell Carcinoma
A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of Southwest Finland.
The purpose of the study is to find out how patients with advanced kidney cancer have been treated in the hospital district of Southwest Finland over time.
- Conditions
- Renal Cell Cancer, Renal Cell Carcinoma, Cancer of Kidney, Cancer of the Kidney
- Trial name
- NCT05363072
- Where
- Finland
- Volunteers
- 1,112 people
- Sponsor
- Pfizer
Intraabdominal Cancers (Various Types)
Mouse Cancer Cell-containing Macrobeads in the Treatment of Human Cancer
This is a phase 1 trial to evaluate the safety and toxicity of mouse kidney cancer cell-containing agarose-agarose macrobeads that are implanted in the abdominal cavity as a proposed biological treatment of patients with…
- Trial name
- NCT00283075
- Testing
- Cancer Macrobead placement in abdominal cavity
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- The Rogosin Institute
Kidney Cancer
Bortezomib in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00276614
- Testing
- bortezomib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Kidney Cancer
Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer
This study is being done in 2 parts. The first part is to determine the dose of RAD001 that should be used in combination with sorafenib.
- Trial name
- NCT00392821
- Testing
- Sorafenib, RAD001
- Where
- 11 sites in United States
- Volunteers
- 78 people
- Sponsor
- SCRI Development Innovations, LLC
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well olaparib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with defects in deoxyribonucleic acid (DNA) damage repair genes that have…
- Conditions
- Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma, Low Grade Glioma
- Trial name
- NCT03233204
- Testing
- Olaparib
- Where
- 113 sites in United States, Puerto Rico
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Kidney Neoplasms
Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer
The study is designed to demonstrate that axitinib (AG-013736) is superior to sorafenib in delaying tumor progression in patients with metastatic renal cell cancer.
- Trial name
- NCT00920816
- Testing
- Axitinib (AG-013736), Sorafenib
- Where
- 125 sites in United States, Bosnia and Herzegovina and 12 more
- Volunteers
- 492 people
- Sponsor
- Pfizer
Congestive Heart Failure, Chronic Obstructive Pulmonary Disease
A Culturally Sensitive Values-Guided Aid for End of Life Decision-Making
The goal of this research agenda is to improve the quality of end-of-life care by explicitly identifying values that will guide the decision-making process, with a particular emphasis on the role of ethnic, racial and cultural…
- Conditions
- Congestive Heart Failure, Chronic Obstructive Pulmonary Disease, Cirrhosis, Colon Carcinoma
- Trial name
- Aim3 (NCT00122135)
- Testing
- Values Inventory (VI)
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- VA Office of Research and Development
Skin Cancer
Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol
Transplant recipients have a high risk to develop skin malignancies. This effect depends on the one hand on the immunosuppressive drugs themselves (i.e., azathioprine) and relates on the other hand on the dosage (i.e.…
- Trial name
- PROSKIN (NCT00866684)
- Testing
- Sirolimus, Azathioprine, Mycophenolate
- Where
- 15 sites in Germany
- Volunteers
- 44 people
- Sponsor
- Charite University, Berlin, Germany
Melanoma, Metastatic Malignant Neoplasm in the Spine
Adaptive Staged Stereotactic Body Radiation Therapy in Treating Patients With Spinal Metastases That Cannot Be Removed by Surgery
This pilot clinical trial studies adaptive staged stereotactic body radiation therapy (SBRT) in treating patients with spinal metastases that cannot be removed by surgery.
- Conditions
- Melanoma, Metastatic Malignant Neoplasm in the Spine, Renal Cell Carcinoma, Soft Tissue Sarcoma
- Trial name
- NCT02527304
- Testing
- Image-Guided Adaptive Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Albert Einstein College of Medicine
Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer
Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney Cancer
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.
- Trial name
- NCT01158222
- Testing
- sunitinib malate
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Case Comprehensive Cancer Center
Cancer, Congestive Heart Failure (CHF)
Outlook Quality of Life Intervention Study
The purpose of this study is to determine whether discussions of life story, forgiveness, and future goals improve quality of life for patients with serious illness.
- Conditions
- Cancer, Congestive Heart Failure (CHF), Chronic Obstructive Pulmonary Disease (COPD), End Stage Renal Disease (ESRD)
- Trial name
- NCT01044290
- Testing
- Life Completion, Attention Control
- Where
- United States
- Volunteers
- 221 people
- Sponsor
- VA Office of Research and Development
Clear-cell Metastatic Renal Cell Carcinoma
MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma
The purpose of this study is to evaluate the efficacy and safety of single-agent MLN0128 and the combination of MLN0128 + MLN1117 compared with everolimus in the treatment of participants with metastatic clear-cell renal cell…
- Trial name
- NCT02724020
- Testing
- Everolimus, MLN0128, MLN1117
- Where
- 36 sites in United States, Canada and 6 more
- Volunteers
- 96 people
- Sponsor
- Millennium Pharmaceuticals, Inc.